Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | TGM2 | P21980 | 5/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600836 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29400961 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178701 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29401249 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29391986 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29958970 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29350360 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178771 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL21462054 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25356530 | 0.99 | KMT2A (0.59) | KMT2AMDM2TGM2TLR2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| CN-119930470-A | Preparation method of N' -Fmoc-L-lysine derivative medical intermediate | 浙江工业大学 | 2025-05-06 | — | — | CN | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | KMT2A 3083/4885MDM2 423/4885TGM2 187/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | KMT2A 3524/4885MDM2 673/4885TGM2 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.